Evidence map›Paper›PMID 39882934›Full record

ArticleMicrobiology spectrum2025

Effectiveness of clindamycin-based exposure strategies in experimental mature staphylococcal biofilms.

S C J van Dun, M Verheul, B G C W Pijls, H Scheper, A M van der Does, P H Nibbering, M G J de Boer

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S C J van DunCenter for Infectious Diseases, Lab of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0001-5174-4462
M VerheulCenter for Infectious Diseases, Lab of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
B G C W PijlsDepartment of Orthopaedics, Leiden University Medical Center, Leiden, the Netherlands.
H ScheperCenter for Infectious Diseases, Lab of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
A M van der DoesPulmoScience Lab, Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands.
P H NibberingCenter for Infectious Diseases, Lab of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
M G J de BoerCenter for Infectious Diseases, Lab of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to increasing antimicrobial resistance and side effects caused by current standard antimicrobial regimens used for treatment of prosthetic joint infection (PJI), alternative options are urgently needed. We aimed to investigate the effect of clindamycin in different exposure strategies against IMPORTANCE: Rifampicin-in combination with another antibiotics-is recommended in all guidelines as first choice treatment of prosthetic joint infections (PJIs), despite adverse interactions and side effects associated with this antibiotic. In a search for alternative approaches, the switch to clindamycin in patients after rifampicin-based antibiotic treatment was found to be effective in some recent observational clinical studies. In our in vitro study, we determined the effect of clindamycin on

Indexed as

Anti-Bacterial AgentsBiofilmsClindamycinStaphylococcus aureusBacterial LoadHumansMicrobial Sensitivity TestsProsthesis-Related InfectionsRifampinStaphylococcal InfectionsAnti-Bacterial AgentsClindamycinRifampinbiofilmclindamycinPJIrifampicinStaphylococcus aureus

Identifiers

PMID39882934
PMCPMC11878082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.